Vanderbilt University Medical Center: Minority Patients Less Likely To Have Amyloid Plaques Necessary For Alzheimer's Treatments
October 04, 2022
October 04, 2022
NASHVILLE, Tennessee, Oct. 4 (TNSjou) -- Vanderbilt University Medical Center issued the following news:
Fewer Black, Hispanic and Asian patients meet biomarker qualifications for landmark treatments that may slow the progression of Alzheimer's disease by targeting amyloid plaques, according to new findings published in JAMA Neurology.
Anti-amyloid monoclonal antibodies break down amyloid plaques in the brain to potentially slow the progression of Alzheimer's . . .
Fewer Black, Hispanic and Asian patients meet biomarker qualifications for landmark treatments that may slow the progression of Alzheimer's disease by targeting amyloid plaques, according to new findings published in JAMA Neurology.
Anti-amyloid monoclonal antibodies break down amyloid plaques in the brain to potentially slow the progression of Alzheimer's . . .